Attached files
| file | filename |
|---|---|
| 10-K/A - AMENDMENT NO. 1 TO FORM 10-K - ZIOPHARM ONCOLOGY INC | d558258d10ka.htm |
| EX-23.1 - EX-23.1 - ZIOPHARM ONCOLOGY INC | d558258dex231.htm |
| EX-23.2 - EX-23.2 - ZIOPHARM ONCOLOGY INC | d558258dex232.htm |
| EX-32.2 - EX-32.2 - ZIOPHARM ONCOLOGY INC | d558258dex322.htm |
| EX-31.2 - EX-31.2 - ZIOPHARM ONCOLOGY INC | d558258dex312.htm |
| EX-31.1 - EX-31.1 - ZIOPHARM ONCOLOGY INC | d558258dex311.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of ZIOPHARM Oncology, Inc. (the “Company”) on Form 10-K/A for the year ended December 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan Lewis, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| /s/ Jonathan Lewis |
| Jonathan Lewis, Chief Executive Officer |
| (Principal Executive Officer) |
| June 28, 2013 |